Vaccine最新文献

{"title":"Risks of removing the age 11–12-year meningococcal vaccine dose from the US immunization schedule","authors":"Jana Shaw , Jaime E. Fergie , James H. Conway , Gary S. Marshall","doi":"10.1016/j.vaccine.2025.127428","DOIUrl":"10.1016/j.vaccine.2025.127428","url":null,"abstract":"","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127428"},"PeriodicalIF":4.5,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144365077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refinement of a novel staphylococcal superantigen-like poly protein vaccine","authors":"Ries J. Langley,&nbsp;Fiona Clow,&nbsp;Kelly Peterken,&nbsp;Janlin Y.H. Chan,&nbsp;John D. Fraser,&nbsp;Fiona J. Radcliff","doi":"10.1016/j.vaccine.2025.127437","DOIUrl":"10.1016/j.vaccine.2025.127437","url":null,"abstract":"<div><div><em>Staphylococcus aureus</em> is a community- and hospital-associated pathogen of global significance. Despite several decades of investment there is no licenced vaccine and antimicrobial resistance is increasing, complicating effective treatment of infection. We have developed a novel fusion vaccine (PolySSL) containing mutated forms of three immune evasion factors, Staphylococcal Superantigen-Like (SSL) proteins 3, 7 and 11, that are common to all <em>S. aureus</em> isolates. Mice given the PolySSL vaccine have a robust specific serum IgG response, attenuated signs of infection, and a significantly reduced <em>S. aureus</em> tissue burden after an intra-peritoneal challenge with <em>S. aureus</em>. A comparison of six different versions of the vaccine (PolySSL 3711, 7113, 7311 and DualSSL 73, 311, 711) suggests inclusion of all three SSLs is required, the 7113 order produces the most significant reduction in bacterial liver and kidney burden, and that SSL7 is the most important component. The likely requirement for a multi-valent vaccine was examined by immunising groups of mice with six PolySSL7113 variants (adjuvanted with AdjuPhos) encompassing most <em>S. aureus</em> strains of clinical significance. SSL7 was confirmed to be the dominant antigen eliciting endpoint titres ≥10⁵ irrespective of the variant used, whereas IgG responses to SSL3 and SSL11 were lower (∼10³) and more variable. The highest inhibition of the interaction between the six wildtype variants of SSL7 and either IgA or complement C5 was typically obtained with variant-matched anti-sera. Conversely, anti-sera from these mice showed failed to stop SSL3 from blocking TLR2 signalling. An improved version of the PolySSL vaccine has been generated by altering the protein order, but these data suggest a multi-valent vaccine will be required to elicit robust inhibitory cross-variant antibody responses. A path to further improvement may be through use of a different adjuvant to broaden and enhance immunity to SSLs 3, 7 and 11.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127437"},"PeriodicalIF":4.5,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144365171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The HBV seroprevalence and immune responses to hepatitis B vaccination among college students from four universities in China","authors":"Yarong Song ,&nbsp;Yongliang Feng ,&nbsp;Feng Jiang ,&nbsp;Xingyan Xu ,&nbsp;Peijuan Yang ,&nbsp;Minmin Liu ,&nbsp;Lili Li ,&nbsp;Chaobi Du ,&nbsp;Huangyuan Li ,&nbsp;Qiong Li ,&nbsp;Jinge Qiao ,&nbsp;Jing Shi ,&nbsp;Le Yang ,&nbsp;Tian Yao ,&nbsp;Gongyuan Zhang ,&nbsp;Jie Wang ,&nbsp;Jie Li","doi":"10.1016/j.vaccine.2025.127408","DOIUrl":"10.1016/j.vaccine.2025.127408","url":null,"abstract":"<div><h3>Background</h3><div>People without effective immunization are vulnerable to infection with hepatitis B virus (HBV). At present, there is no appropriate hepatitis B vaccination strategy for HBV-susceptible adults. We aim to assess the long-term effect of neonatal hepatitis B immunization and HBV markers among college students, so as to explore hepatitis B vaccination strategies suitable for high-risk group.</div></div><div><h3>Methods</h3><div>The enrolled freshmen from four universities were initially tested for hepatitis B screening using colloidal gold test strips. Subjects with positive hepatitis B surface antigen (HBsAg) or negative hepatitis B surface antibody (anti-HBs) were further confirmed using Abbott reagents. HBsAg and anti-HBs double negative individuals were administered hepatitis B vaccination.</div></div><div><h3>Results</h3><div>Using Abbott reagents, we confirmed that among 3242 enrolled freshmen, 1604 (49.5 %) were negative for both HBsAg and anti-HBs, and 27 (0.8 %) were HBsAg-positive. Among the double negative freshmen, 1263 received hepatitis B vaccination. After the first and second dose of hepatitis B vaccine, the protective anti-HBs seroconversion rates reached 91.4 % and 98.5 %, respectively. Only one (0.1 %) freshman was still negative for anti-HBs after the third dose of hepatitis B vaccine. In addition, 96.3 % (104/108) of the fresmen who failed to achieve protective anti-HBs seroconversion after the first dose of hepatitis B vaccine had a baseline anti-HBs level &lt; 2 mIU/mL.</div></div><div><h3>Conclusion</h3><div>The HBsAg prevalence among college students has been significantly reduced after the integration of hepatitis B vaccine into Expanded Program on Immunization, but the rate of seroprotective anti-HBs among these students remains low. Hepatitis B vaccination or booster dose is advised for a high-risk group who have negative anti-HBs, and two doses of hepatitis B vaccine are advised for those with anti-HBs &lt; 2 mIU/mL.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127408"},"PeriodicalIF":4.5,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144366955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bivalent fusion protein vaccine induces protective immunity against SARS-CoV-2 and Staphylococcus aureus","authors":"Menghan Ma ,&nbsp;Jintao Zou ,&nbsp;Xiaoqiang Zeng ,&nbsp;Xuan Hu ,&nbsp;Wei Zhang ,&nbsp;Yi Wang ,&nbsp;Xiaopeng Zhang","doi":"10.1016/j.vaccine.2025.127411","DOIUrl":"10.1016/j.vaccine.2025.127411","url":null,"abstract":"<div><div>Viral-bacterial co-infections pose significant global health challenges. Currently, there are limited vaccines that target both viral and bacterial pathogens simultaneously. In this study, we present HRBD, a novel fusion protein vaccine combining the receptor-binding domain (RBD) of SARS-CoV-2 and a detoxified α-hemolysin mutant (Hla^H35A) from <em>S</em><em>.</em> <em>aureus</em>. When tested in mice, HRBD induced robust IgG1-dominated antibody responses against both antigens, leading to neutralizing effects against SARS-CoV-2 pseudovirus (NT₅₀ ∼ 10³) and <em>S. aureus</em> hemolytic activity (NT₅₀ ∼ 10²). HRBD promoted a Th2 immune response with increased IL-4 levels, while also boosting IFN-γ production. Importantly, HRBD showed dose-sparing efficacy, achieving similar immune responses as high-dose single or mixed-antigen vaccines with half the antigen amount. Functional tests confirmed that HRBD sera could neutralize Hla-induced cell lysis and block SARS-CoV-2 entry and syncytium formation. HRBD vaccination protected hACE2 transgenic mice against the co-infection of SARS-CoV-2 pseudovirus and <em>S. aureus</em>. These results suggest that HRBD is a promising candidate for preventing SARS-CoV-2 and <em>S. aureus</em> co-infections.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127411"},"PeriodicalIF":4.5,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144365172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 mRNA or viral vector vaccine type and subject sex influence the SARS-CoV-2 T-cell response","authors":"Sherry Tong ,&nbsp;Sean M. Litwin ,&nbsp;Elissa S. Epel ,&nbsp;Jue Lin ,&nbsp;Stacy S. Drury ,&nbsp;Frederick M. Hecht ,&nbsp;James E. Robinson ,&nbsp;Aric A. Prather ,&nbsp;Elizabeth B. Norton","doi":"10.1016/j.vaccine.2025.127420","DOIUrl":"10.1016/j.vaccine.2025.127420","url":null,"abstract":"<div><div>Severe SARS-CoV-2 infection has been partially controlled by vaccination, though issues in duration and breadth of protection remain. Few studies investigate factors driving diversity in the cellular immune response to vaccination. Here, we evaluated T-cell immunity in 60 healthy adults and its relationship to vaccine and subject-specific variables.</div><div>CD4 and CD8 T-cells from COVID-19 vaccinated subjects expressed spike-specific activation-induced markers (AIM+) and cytokines. Overall, AIM+ CD8 T-cells correlated best with neutralizing antibodies and were more strongly expressed by females than males. Unique patterns in CD4 T-regulatory cells, cytokine profiles, and central and effector memory subsets were observed between Moderna, Pfizer, and Janssen vaccinees and by subject-specific factors. Sex differences outweighed differences in BMI and age.</div><div>Thus, COVID-19 vaccine type and subject sex impacted the magnitude and quality of the spike-specific T-cell response. These results help explain differences in durability and memory between mRNA and adenovirus vector based COVID-19 vaccines and suggest targets for improved vaccine design.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127420"},"PeriodicalIF":4.5,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144365170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seroprevalence of Immunoglobulin G against measles and rubella over a 12-year period (2009–2021) in Kilifi, Kenya and the impact of the Measles-Rubella (MR) vaccine campaign of 2016","authors":"C.N. Mburu ,&nbsp;J. Ojal ,&nbsp;R. Selim ,&nbsp;R. Ombati ,&nbsp;D. Akech ,&nbsp;B. Karia ,&nbsp;J. Tuju ,&nbsp;A. Sigilai ,&nbsp;G. Smits ,&nbsp;P.G.M. van Gageldonk ,&nbsp;F.R.M. van der Klis ,&nbsp;S. Flasche ,&nbsp;E.W. Kagucia ,&nbsp;J.A.G. Scott ,&nbsp;I.M.O. Adetifa","doi":"10.1016/j.vaccine.2025.127425","DOIUrl":"10.1016/j.vaccine.2025.127425","url":null,"abstract":"<div><h3>Background</h3><div>Measles and rubella have been targeted for elimination by the World Health Organization<strong>.</strong> Age-specific population immunity to measles and rubella is important to assess progress towards elimination but data are scarce. We conducted seroprevalence surveys to identify disease-specific population immunity profiles in children and adults in Kilifi.</div></div><div><h3>Methods</h3><div>Sera from cross-sectional surveys in the Kilifi Health Demographic Surveillance System (2009–2021) were analysed using a fluorescent bead-based multiplex immunoassay. Bayesian multilevel regression with post stratification was used to obtain seroprevalence estimates adjusted for the underlying population and assay performance. Associations between seropositivity and age, sex, location and ethnic group were assessed using a mixed effects logistic regression.</div></div><div><h3>Results</h3><div>Measles-adjusted seroprevalence showed a significant increase from 88 % in 2009 to 93 % in 2021 (τ = 0.875, <em>P</em> = 0.01). Seropositivity was significantly higher in all age groups compared to those under 9 months. Seroprevalence among children ineligible for the first measles vaccine dose (MCV1) remained low (10–57 %), whereas MCV1-eligible children (9–17 months) had higher seroprevalence (68–91 %). Adult measles seroprevalence exceeded 96 %. Rubella seroprevalence followed a similar pattern, with adults above 88 %. Following the MR campaign, measles seroprevalence increased from 92 % to 96 % in eligible children, while rubella seroprevalence rose from 45 % to 82 %.</div></div><div><h3>Conclusion</h3><div>Population immunity for measles significantly increased over the 12-year period suggesting improvement in immunisation program performance. To reduce reliance on frequent SIAs, efforts should focus on optimizing both the timing and coverage of routine doses, particularly ensuring higher coverage of MCV2. The introduction of rubella vaccination has positively impacted immunity in children. Sustaining this immunity is essential to prevent potential gaps in older age groups, which could increase the risk of Congenital Rubella Syndrome (CRS) in infants.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127425"},"PeriodicalIF":4.5,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144331283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Recombinant BCGΔBCG1419c protects outbred mice against M. tuberculosis challenge” [Vaccine 61 (2025) 127347]","authors":"Sherry L. Kurtz ,&nbsp;Victoria Gould ,&nbsp;Mario A. Flores-Valdez ,&nbsp;Karen L. Elkins","doi":"10.1016/j.vaccine.2025.127418","DOIUrl":"10.1016/j.vaccine.2025.127418","url":null,"abstract":"","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127418"},"PeriodicalIF":4.5,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144331310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual Aβ/tau epitope vaccines: a poorly explored strategy for Alzheimer's disease immunotherapy","authors":"Karen León-Arcia,&nbsp;Gabriela Pérez-Leal,&nbsp;Heidi Quintero-Álvarez,&nbsp;Diana Iris Zamora-Loyarte,&nbsp;Mailén López-Armenteros,&nbsp;Alexandra de la Caridad Sánchez-Quesada,&nbsp;Yaimeé Vázquez-Mojena","doi":"10.1016/j.vaccine.2025.127414","DOIUrl":"10.1016/j.vaccine.2025.127414","url":null,"abstract":"<div><div>Alzheimer's disease (AD) presents a growing public health challenge that urgently requires effective disease-modifying therapies. Active immunotherapy appears to be a promising strategy in AD drug development, offering advantages over passive immunization in terms of prophylactic potential and cost-effectiveness. We systematically reviewed anti-Aβ and anti-tau active immunization strategies over the past 25 years, identifying 577 unique antigenic formulations. Only 3.5 % have progressed to clinical trials, with none yet approved. Notably, only three strategies targeted both Aβ and tau epitopes (Aβ1–11 and tau2–18), despite the potential of multi-target approaches for AD's multifactorial pathology. Given the synergistic role of Aβ and tau in disease progression, dual-target vaccines remain a critical and underinvestigated area with significant therapeutic promise. This review underscores the need to expand research into multi-target immunotherapies that better address AD's complexity, potentially improving prevention and treatment outcomes.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127414"},"PeriodicalIF":4.5,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144335783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Communication interventions to reduce parental vaccine hesitancy: A systematic review","authors":"Sinchul Jwa ,&nbsp;Yousuke Imanishi ,&nbsp;Marie T. Ascher ,&nbsp;Matthew Z. Dudley","doi":"10.1016/j.vaccine.2025.127401","DOIUrl":"10.1016/j.vaccine.2025.127401","url":null,"abstract":"<div><h3>Introduction</h3><div>Vaccine hesitancy among parents and caregivers is a growing issue that can lead to reduced vaccine coverage and corresponding outbreaks of disease. Different interventions to reduce vaccine hesitancy have been developed, including the use of remote online communication that has become more common during the COVID-19 pandemic, but their impacts and effectiveness are unclear. In this systematic review, we aimed to identify effective types of communication that reduce vaccine hesitancy.</div></div><div><h3>Methods</h3><div>Multiple online databases were searched on April 1st, 2022 as well as March 18th, 2024. Included articles studied the impact of communication interventions aiming to reduce vaccine hesitancy among parents and caregivers of young children. Interventions targeting adolescent or adult vaccines were excluded. Potential biases or limitations that may affect the results of each study were evaluated.</div></div><div><h3>Results</h3><div>Out of 3873 identified articles, 33 studies were included in this review, and 25 showed effectiveness. Among the 25 effective communication interventions, 11 were in-person and interactive, 11 were neither in-person nor interactive, 3 were interactive but not in-person, and 2 were in-person but not interactive.</div></div><div><h3>Discussion</h3><div>Communication interventions can reduce vaccine hesitancy and increase childhood vaccine coverage. Although different types of interventions can reduce vaccine hesitancy and increase childhood vaccine coverage, especially by in-person and interactive communication interventions, further research is needed to elucidate the components that make such interventions impactful in different settings. These findings are particularly relevant for clinicians and public health officials striving to reduce vaccine hesitancy and increase vaccine uptake among children.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127401"},"PeriodicalIF":4.5,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144335782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 vaccine (NVX-CoV2373 and NVX-CoV2540) doses and virus strain match impact sex- and age-specific immunity and protection in mice","authors":"Sabal Chaulagain ,&nbsp;Jaiprasath Sachithanandham ,&nbsp;Jennifer A. Liu ,&nbsp;Patrick S. Creisher ,&nbsp;Han-Sol Park ,&nbsp;John S. Lee ,&nbsp;Mimi Guebre-Xabier ,&nbsp;Nita Patel ,&nbsp;Gale Smith ,&nbsp;Andrew Pekosz ,&nbsp;Sabra L. Klein","doi":"10.1016/j.vaccine.2025.127409","DOIUrl":"10.1016/j.vaccine.2025.127409","url":null,"abstract":"<div><div>Sex and age impact immune responses to diverse vaccines. Using a preclinical mouse model, we investigated immune responses to a COVID-19 spike (S) protein-based vaccine and booster doses in adult (25 weeks) and aged (64 weeks) male and female C57BL/6 mice. Mice were intramuscularly vaccinated with either two doses of NVX-CoV2373 (Ancestral Wuhan-Hu-1) or two doses of NVX-CoV2373 followed by a booster of NVX-CoV2540 (Omicron BA.5) in 3-week intervals. Steroid concentrations, antibody titers, and immune cell frequencies in draining lymph nodes were quantified. Three weeks post-boost, subsets of mice were challenged with SARS-CoV-2 (Mu variant B.1.621) to measure cross-protection against an antigenically distinct strain. After two ancestral vaccine doses, adult females had greater binding antibody titers than either adult males or aged females, that were positively correlated with circulating estradiol concentrations. Adult females also had greater cross-neutralizing antibodies and had lower viral titers in respiratory tissues following live virus challenge than adult males. Aged mice, particularly males, had lower antibody titers and frequencies of B and follicular helper T cells than adult mice that were not cross-protective against B.1.621 challenge. Immunization with the BA.5 booster improved antibody responses and B and T cell frequencies in both adults and aged mice, eliminating sex and age differences in immunity and protection from SARS-CoV-2 challenge. These data highlight that there are limits to cross-protective immunity, particularly among males and aged individuals, that can be improved through booster doses that more closely match the challenge SARS-CoV-2 virus.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127409"},"PeriodicalIF":4.5,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144331284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}